

## Oasmia Pharmaceutical Appoints Dr. Heidi B. Ramstad as Chief Medical Officer

Uppsala, Sweden, January 29, 2021 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, announces the appointment of Dr. Heidi B. Ramstad as Chief Medical Officer reporting to Dr. Francois Martelet, Chief Executive Officer. Dr. Ramstad will join Oasmia in her new role no later than March 1st, 2021.

Dr. Ramstad replaces Dr. Reinhard Koenig, Oasmia's acting Chief Medical Officer. Dr. Koenig, who is based on the East Coast of the US, will continue to advise Oasmia at a senior level.

Dr. Ramstad has more than 20 years' experience as a medical doctor and biopharmaceutical executive in the healthcare sector. Recent positions include working for Nisonic AS as Chief Medical Officer and as Managing Director at NorMed Consulting. Dr. Ramstad has also worked for a number of blue-chip pharmaceutical companies including Roche and GSK, serving as Country Medical Director for Norway, and Pfizer, serving as Nordic Medical Affairs Manager.

Dr. Ramstad received her Graduate degree in Medicine from the Norwegian University of Science and Technology in June 2000.

**François Martelet, M.D., CEO of Oasmia, commented:** "We are delighted to have Heidi join the Oasmia team at this important juncture for the Company as we continue to implement our strategy of accelerating growth and generating long term value. Heidi's depth of medical experience will be instrumental as we look to develop and grow our pipeline of specialty pharma products. I'd also like to thank Dr. Reinhard Koenig wholeheartedly for his significant contribution to Oasmia as acting CMO."

**Dr. Ramstad, newly appointed CMO of Oasmia, said:** "I am thrilled to be joining the Oasmia team at this important time in the Company's development. I look forward to working alongside the wider team to help progress Oasmia's pipeline, help evaluate opportunities to apply Oasmia's proprietary XR-17™ solubility-enhancing technology platform, and potential M&A and in-licensing opportunities to benefit patients in oncology and other therapeutic areas."

-ENDS-

**For more information:**

**Oasmia Pharmaceutical AB**

Francois Martelet, Chief Executive Officer  
Phone: +46 18-50 54 40  
E-mail: [IR@oasmia.com](mailto:IR@oasmia.com)

**Consilium Strategic Communications**

Jonathan Birt, Chris Welsh, Ashley Tapp  
Phone: +44 (0)20 3709 5700  
E-mail: [oasmia@consilium-comms.com](mailto:oasmia@consilium-comms.com)

### **About Oasmia Pharmaceutical AB**

Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on the Company's proprietary drug delivery technology platform XR-17™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Oasmia's shares are traded on the Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit [www.oasmia.com](http://www.oasmia.com).

### **Attachments**

---

[Oasmia Pharmaceutical Appoints Dr. Heidi B. Ramstad as Chief Medical Officer](#)